Trials / Unknown
UnknownNCT06223646
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Characterization of KQ-2003 for Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, dose-escalation/expansion phase 1/2a study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for patients with Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | KQ-2003 CAR T-cells | KQ-2003 CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting both human B cell maturation antigen (anti-BCMA CAR) and CD19 antigen molecules (anti-CD19 CAR) simultaneously as a cellular therapy. |
Timeline
- Start date
- 2024-01-11
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2024-01-25
- Last updated
- 2024-01-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06223646. Inclusion in this directory is not an endorsement.